Introduction

Acute bacterial meningitis (ABM) is a life-threatening, infectious disease that affects patients of all ages. Even with the best medical treatment [1], it is associated with severe morbidity and mortality [2]. The classical symptoms include fever, headache, neck stiffness, and an altered level of consciousness. More than 95% of patients with ABM will present with at least two of these symptoms [3]. The course of ABM is accompanied by an elevated intracranial pressure (ICP) in up to 93% of patients [4]. The rise in ICP is multifactorial, with major elements being cerebral edema of vasogenic, cytotoxic, or interstitial types [5]. Other mechanisms contributing to elevated ICP include the loss of cerebrovascular autoregulation with increased vasodilation, venous thrombophlebitis producing venous congestion, and the development of hydrocephalus due to impaired cerebrospinal fluid (CSF) circulation and reabsorption [5, 6].

The most feared complication of elevated ICP is brain herniation, which may lead to coma or death [7]. Elevated ICP and its consequences have been described among the primary causes of death in patients with ABM [8,9,10]. Although it is well known that early diagnosis followed by timely administration of corticosteroids and antibiotics are crucial for the successful management of these patients, there is no consensus on whether to monitor ICP or how to manage ICP elevation in these patients [2].

The current guidelines on the treatment of ABM, issued by the European Society of Clinical Microbiology and Infectious Diseases, recommend a computed tomography (CT) scan on suspicion of elevated ICP and/or intracranial space-occupying lesions (focal neurologic deficits, new-onset seizures, and Glasgow Coma Scale (GCS) of < 10, all indicators of elevated ICP), before performing a lumbar puncture [6]. However, CT scanning cannot accurately assess ICP and lacks temporal resolution [11, 12]. Instead, the use of more accurate invasive ICP monitoring methodologies may be warranted [13, 14]. However, the timing and indications for invasive ICP monitoring in the management of ABM remain unclear [2, 14]. Although some authors suggest that invasive ICP monitoring should be considered in patients with ABM with a GCS score below 8 [14,15,16], others argue that ICP monitoring should be initiated earlier in the course of the disease to ensure the best neurological outcomes [17]. The guidelines for bacterial central nervous system infections issued by the Swedish Society for Infectious Diseases suggest that invasive ICP monitoring and treatment should be initiated in rapidly deteriorating or comatose patients with an elevated pressure on lumbar puncture [18]. Similarly, the European Society of Clinical Microbiology and Infectious Diseases has recognized the need for further research to establish recommendations for the use of ICP monitoring and ICP-based management approaches in patients with ABM. In line with that, the aim of this systematic review was to investigate the effect of invasive ICP monitoring and management on morbidity and mortality for the treatment of community-acquired ABM.

Methods

This systematic review is in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses [19] guidelines (Supplementary file 1, Table S1). The review protocol was registered within the International Prospective Register of Systematic Reviews (PROSPERO) (Registration identifier CRD42022332706. Date of registration 25/05/2022). Our review complies with all ethical guidelines and did not require ethical approval.

Eligibility Criteria

Types of Studies

The systematic review only included peer-reviewed human studies, regardless of the date of publication. Case reports, reviews, editorials, letters, and conference abstracts were excluded.

Studies in the English, French, Swedish, and Norwegian languages were eligible for inclusion.

Type of Population

Only studies on patients with community-acquired ABM were considered. Studies on viral, cryptococcal, tuberculous meningitis, or iatrogenic meningitis were excluded, with the exception of articles in which these etiologies constituted a minority of the study cohort. When possible, these patients were excluded to better serve the scope of this review.

Type of Intervention

The aim of this review was to summarize the current evidence on the efficacy of ICP-based management strategies for community-acquired ABM. Only studies reporting the use of a technology, intervention, or treatment for either the detection or the management of elevated ICP in community-acquired ABM were considered.

Type of Outcome Measures

The main outcomes of interest to this review were morbidity and mortality. Other outcomes included length of hospital stay, ICP-related metrics (including opening ICP, overall mean or median ICP, number of ICP peaks, etc.), and complications related to invasive ICP monitoring or management. Studies without any outcome of interest were excluded.

Databases and Search Strategy

Articles were selected from four different electronic search engines and databases including PubMed, Web of Science, Embase, and the Cochrane Library. The search strategy used in this review combined the following terms using simple Boolean operators: Intracranial Pressure AND management OR monitor* AND bacterial meningitis (Supplementary file 1, Table S2).

Study Selection

Searches across all search engines from inception until October 2022, yielded a total of 403 publications. After duplicate removal, the remaining 307 studies were transferred to Rayyan where the selection process took place [20]. The studies were first screened based on titles and abstracts by two independent and blinded reviewers (I.P. and V.G.E.). Then, full-text articles were assessed by three independent and blinded reviewers (V.G.E., A.E.T., and E.E). Inter-reviewer conflicts were resolved through discussion.

Data Extraction and Synthesis

Data extraction adhered to a predefined extraction template encompassing the following: first author last name, date of publication, study characteristics and design, sample size, ABM diagnosis criteria, control group, ICP monitoring technique, indications for monitoring, ICP management approach, indications for management, and outcomes including patient mortality and morbidity, invasive monitoring-related complications, and posttreatment ICP-related outcome measures.

Extraction was performed by two independent authors (V.G.E, and M.G.), and the two extraction sheets were cross checked by a third blinded and independent author (A.E.T).

Because of the small number and heterogeneity of the studies, including different population types, comparators, devices used, and primary outcome measures, a meta-analysis could not be performed. Instead, we opted for a narrative and qualitative description of the data.

Risk of Bias and Evidence Certainty Assessment

Risk of bias was assessed using the Newcastle–Ottawa Scale, a scoring system designed for observational studies and allowing a maximum of 9 points per study. Because two of the studies were interventional in nature, the Newcastle–Ottawa Scale could not be used, and the National Institutes of Health quality assessment tool was employed instead. The results of this assessment are provided (Supplementary file 1, Tables S3 and S4). The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach was employed to rate the body of evidence supporting the review’s key findings [21]. A GRADE summary of findings table assembled using the GRADEpro Guideline Development Tool is provided [22].

Results

Baseline Characteristics and Risk of Bias Assessment

After initial title and abstract screening, 33 remaining articles were gathered in full-text form. The final screening process resulted in 16 exclusions, leaving a total of 17 studies to be included. After screening of the reference lists of the included studies, one more eligible study was identified, amounting to a total of 18 included studies (Fig. 1).

Fig. 1
figure 1

PRISMA 2020 flow diagram for new systematic reviews which included searches of databases, registers, and other sources. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Nine retrospective cohort studies, seven case series, and two trials, in which one was randomized, were included in this review (Table 1). The majority of the studies were conducted in Europe (n = 11): six studies in Sweden, and one each in Denmark, Norway, Germany, Belgium, and France. Four were performed in North America, and three were performed in India. Sample sizes varied between 3 and 2237 patients (median 38; interquartile range 15–100). Among these, a total of 616 patients (median 16; interquartile range 10–36) received any form of invasive ICP monitoring (Fig. 2). Eight studies targeted the adult population, seven targeted the pediatric population, two studies had mixed populations, and one study was poorly defined. In most studies, the diagnosis of ABM relied on a combination of clinical presentation, CSF analysis, and microbial cultures. Two studies failed to mention how the diagnosis of meningitis was established. Critical appraisal of the studies showed that most had a moderate to high risk of bias, whereas only a few studies had a low risk of bias (n = 4).

Table 1 Baseline characteristics and bias scores of the included studies
Fig. 2
figure 2

Logarithmic-scale histogram showing the sample size and number of patients treated with invasive monitoring in each of the included studies. ICP, intracranial pressure

ICP Monitoring

Intracranial pressure in patients with ABM was measured using invasive methods in 18 studies, with external ventricular drain (EVD) and intraparenchymal monitoring devices being the most widely used (Table 2). Six and three studies reported the use of either EVD or intraparenchymal monitoring devices, respectively. Seven other studies reported the use of both, with EVD being most often chosen as the first alternative. One study used subdural catheters and another one used lumbar drain for ICP measurement [9].

Table 2 The tools used by each study for ICP measurement, estimation, or monitoring

Management of patients in need of invasive ICP monitoring is typically performed at an intensive care unit. In studies in which this information was available (13/18), a deteriorating neurological status was the main indication. In some studies (11/18), authors used standardized and objective metrics such as the GCS, or the Reaction Level Scale. In other studies, different surrogates were used, such as clinical and radiological signs or perceived severity of the illness (7/18). The GCS and Reaction Level Scale thresholds for initiation of ICP monitoring were generally set to below 7–9 or above 3, respectively (Table 2).

All six studies that reported the use of CT in conjunction with invasive techniques confirmed that CT was less reliable and could severely underestimate a raised ICP [4, 16, 17, 23,24,25]. Muralidhar et al. [26] found that once abnormal head CT findings were detected, clinical outcomes were remarkably worse. Similar findings were noted by Wettervik et al. [24], who found a significant association between both compression of the basal cisterns on admission CT and pupillary abnormalities and unfavorable outcomes or death. Wettervik et al. [24] did not find any association between elevated ICP and positive CT findings, which they attributed to the effective early detection and management of elevated ICP before the development of radiological signs.

Management of Elevated ICP

Intracranial pressure or cerebral perfusion pressure (CPP)-targeted management protocols were implemented in all studies. ICP in combination with CPP-targeted management was used in six studies, whereas the rest mainly involved ICP-centered approaches. Studies applying CPP-targeted management used fluid resuscitation as well as vasopressors to maintain CPP by increasing the mean arterial pressure. Studies focusing on ICP-targeted management employed different combinations of ICP-lowering strategies, including osmotherapy, CSF drainage, thiopental, and decompressive craniotomy. Only the study by Kumar et al. [27] presented a thorough comparison of the two strategies in a randomized controlled trial. In that study, CPP-targeted management was found to be significantly superior to ICP-targeted management in terms of the 90-day mortality (p = 0.020).

The ICP-lowering treatments were diverse and included invasive procedures (18/18 studies), hyperventilation (6/18 studies), thiopental and sedation (8/18 studies), osmotherapy typically with mannitol (3/18 studies), the Lund concept (2/18 studies), and hypothermia (1/18 studies). The invasive procedures included EVD (13/18), decompressive craniotomy (4/18), lumbar drain (LD) (3/18), and ventriculoperitoneal (VP) shunt (1/18).

Overall, the studies lacked detailed and standardized treatment protocols. There was typically an incremental and stepwise implementation of the treatments. Hyperventilation and osmotherapy were often used early, whereas thiopental and decompressive surgery were last resorts for the treatment of refractory rises in ICP. The most common indication for CSF drainage was the detection of an elevated ICP, whereas for decompressive surgery, an elevated ICP refractory to all other treatments was usually a prerequisite [17, 24, 28, 29]. In three studies, CSF drainage was used on acute neurological deterioration, which suggested impending cerebral herniation. Details on the indications as presented in each study are presented in Table 3. Complications associated with the use of invasive procedures were seldom reported. EVD-related adverse events, mainly composed of central nervous system infections, were reported in six patients from two different studies [27, 30]. Both studies were conducted at the same institution in India.

Table 3 ICP management strategies that were employed in the included studies

Patient Outcomes

Length of Hospital Stay

The average length of hospital stay was reported in seven studies and varied from 6 to 32 days. In two studies, shorter hospital stays were associated with the placement of an LD as compared with no LD (14 vs. 17 days; p = 0.25) [31] and CPP-targeted management as compared with ICP-targeted management (13 vs. 18 days; p = 0.002), of which only the latter was significant [27]. In another study, the authors found that patients receiving ICP monitoring had significantly longer hospital stays (p = 0.010), even after propensity score matching of the cohorts [32]. Moreover, hospital stay tended to be longer in pediatric studies compared with adults. The average hospital stay ranged between 6 and 17 days in adult studies and between 13 and 32 days in pediatric studies.

ICP Outcomes

Intracranial pressure values were quantitatively reported in 15 studies, in which only five adopted a longitudinal approach and also presented follow-up values post ICP treatment (Table 4). One of these five studies randomly assigned patients to either ICP or CPP-targeted management plans and found a decrease in mean ICP in both groups by an average of 9 and 15 mm Hg, respectively [27]. There was a significant reduction in the percentage of patients with ICP elevation from 100 to 0% in a study using the Lund concept [23], and from 28 to 9% in a study using a stepwise management strategy combining hyperventilation, CSF drainage, and thiopental [24]. In a fourth study, a management strategy including thiopental, mechanical hyperventilation, EVD, and hypothermia had reportedly failed in one of two patients [16]. Treatment failure was accompanied by death of one of the patients, whereas the second patient, in whom treatment had shown effect, recovered. The last study recorded a trend of normalizing ICP in patients who had received ICP-lowering therapy according to the Lund concept. This trend was especially notable in patients who had survived compared with nonsurvivors (61.2 vs. 19.4 mm Hg; p = 0.001) [4].

Table 4 Length of hospital stay, posttreatment ICP and CPP, mortality, and morbidity

Morbidity

The morbidity rate was reported in 12 studies and varied between 16 and 100%. Eleven of these studies had further information regarding the nature of the complications, mostly hearing loss, neurological deficits, and headaches. In one study, authors recorded a significant reduction in morbidity with ICP monitoring and CSF drainage added to the treatment strategy compared with the control group, which was not monitored (46 vs. 68%; p < 0.05) [9]. A randomized trial comparing ICP and CPP-targeted management found the latter to substantially decrease the risks of both hearing loss (8.9 vs. 37.1%; p = 0.005) and neurological deficits (53.3 vs. 82.9%; p = 0.005), an effect that persisted at the 90-day follow-up (37.8 vs. 70.6%; p = 0.004) [27].

Mortality

Mortality data were reported in all studies and ranged from 0 to 67%. Abulhasan et al. [31] reported zero mortality in a retrospective cohort of 11 adult patients, in whom either EVD or intraparenchymal ICP monitoring was used. The patients were treated according to an ICP-targeted management strategy in which CSF diversion through LD was the primary treatment. In the comparison group in which LD was not used, a mortality of 15% was seen (p = 0.0001) [31]. This was despite the fact that worse admission neurologic scores were found among patients receiving management with LD. Control or comparison groups were also present in four other studies. One of the studies, a nonrandomized trial, showed a significant reduction in the mortality of patients with ABM in their intervention group compared with the controls (10 vs. 30%; p < 0.05). In addition to the standard treatment given to both groups, the intervention group had ICP monitoring, and CSF drainage as needed to maintain ICP below 20 mm Hg and CPP more than 50 mm Hg [9]. Another study comparing patient mortality found a lower mortality rate in patients with ICP monitoring compared with controls (6.2 vs. 12%). Monitoring led to CSF drainage in almost half of the patients. In the study, the authors also reported a mortality rate of 80% among patients having received last-tier treatment, including thiopental and decompressive craniectomy [24]. Additionally, one study assessed the benefit of CSF drainage through either EVD or VP shunt compared with control patients who had only standard antibiotic treatment. Their results suggested modest improvements in patient outcomes for the CSF drainage groups, especially through VP shunt [30]. The last study, a randomized controlled trial of pediatric ABM cases that compared ICP and CPP-targeted management found the latter to be associated with a lower mortality (18.2 vs. 38.2%; p = 0.02) [27].

In two studies adopting the Lund concept for the treatment of 12 and 15 patients, respectively, the mortality rates were 16.7% [23] and 33% [4], respectively. In the latter [4], it was observed that patients who did not receive or did not respond to treatment with the Lund concept were more likely to die.

ICP and CPP values of survivors could be contrasted with those of nonsurvivors in seven studies in which this information was present [23,24,25, 27, 33, 34]. Finally, six studies reported higher ICP and/or lower CPP values in nonsurvivors compared with survivors [4, 9, 23, 27, 33, 34].

Evidence Certainty

The GRADE approach was used to assess the certainty of the body of evidence associated with the main findings in this review (Table 5).

Table 5 Narrative GRADE evidence summary table

Discussion

This systematic review gathered published evidence on different ICP monitoring and management strategies in community-acquired ABM. ICP monitoring in ABM is of great importance because a significant proportion of patients will develop elevated ICP, and mortality in these patients has repeatedly been correlated to intracranial hypertension. These correlations rely on higher ICP values among nonsurvivors [23,24,25, 27, 33, 34] or autopsy findings, such as uncal or cerebellar herniation indicative of elevated ICP [9, 10, 16, 24, 31, 35].

Methods to Detect Elevated ICP

In this review, most authors argued against the use of CT to rule out ICP elevation [4, 16, 17, 23,24,25]. One study showed that an elevated ICP with visible head CT changes correlated with unfavorable outcomes [26]. CT findings have previously been associated with late stages and end stages of the clinical course in ABM and may consequently be of limited use in improving outcomes [11, 24].

Currently, the mainstay of ICP monitoring relies on invasive measuring devices because of their established superiority to noninvasive alternatives [13, 36,37,38]. The disadvantages associated with invasive ICP measurement may include availability issues, contraindications [29, 39], and associated risks, such as hemorrhages, iatrogenic central nervous system infections [40], and brain herniation [41].

As one study pointed out, the fear of potential adverse events resulting from the use of invasive techniques may be delaying their use in clinical practice [42]. This reasoning may defeat the purpose of such devices, as their associated benefits often result from early detection of abnormally elevated ICP. Because of the heterogeneity between the included studies, any quantitative analysis comparing the different ICP monitoring strategies for ABM would be inappropriate. However, EVD remains the gold standard for ICP monitoring and may hence be considered in the management of ABM, when indicated [14, 17, 24].

ICP Management

In this review, CSF drainage using an EVD was the most common strategy for the treatment of elevated ICP, but the use of LD or VP shunts was also reported [25, 28, 31]. Adverse events directly related to the use of these strategies were seldom reported [27, 30]. The reviewed literature clearly indicates the lack of a standardized protocol for the detection and management of elevated ICP in ABM. Most of the strategies were either based on an arbitrary combination of treatments or a tier-based scheme that often differed between studies. The granularity of the published data did not allow a thorough comparison of different strategies, and consequently conclusions regarding the relative efficacy of different treatments could not be made. For instance, CPP-targeted management was directly compared with ICP-targeted therapy only in a pediatric population, in which it was superior in terms of the 90-day mortality. Nonetheless, based on the few comparative studies, some points can be highlighted:

  1. 1.

    In the adult population, CSF drainage through an EVD in addition to conventional therapy was superior to conventional therapy alone, reducing both morbidity and mortality [9].

  2. 2.

    In the adult population, CSF drainage through an LD in addition to conventional therapy was superior to conventional therapy alone, reducing both morbidity and mortality [31].

  3. 3.

    In the adult population, CSF drainage through a VP shunt in addition to conventional therapy showed modest improvements in terms of patient outcomes [30].

  4. 4.

    In a pediatric population, CPP-targeted management with vasopressors was superior to ICP-targeted management based on fluids, osmotherapy, and hyperventilation, without CSF drainage [26].

Overall, findings from several studies highlight the potential mortality benefits of ICP management in patients with severe ABM [9, 24, 31].

In summary, although weak, the evidence points toward certain advantages with the use of invasive ICP monitoring and ICP-based treatment approaches in conjunction with conventional treatment approaches, in selected cases of ABM.

Limitations

The limitations of this review mainly derive from the inherent limitations of the included articles. Namely, many of the included studies had small sample sizes, intermediate to high risks of bias, and observational study designs, with most being retrospective cohort or case series. Only two studies were interventional, and only one was randomized. A second limitation resides in the heterogeneity of study designs, including both parallel and sequential designs, interventional and observational studies, as well as different inclusion criteria and management approaches. Additionally, the primary end points also differed between the studies. Consequently, the heterogeneity of the available data precluded a quantitative meta-analysis and limited the generalizability of the results. In addition, most of the studies failed to report inclusion and exclusion criteria, which may limit external validity of the results. Finally, only studies in the English, French, Swedish, and Norwegian languages were screened for inclusion, which may also hamper the representativity and generalizability of the results.

Future Perspectives

Several of the studies in this review concluded the need for randomized controlled trials in determining the role of ICP monitoring and management in the treatment of ABM. At this point, however, we find that a benefit of ICP-based management in ABM has been suggested and that careful ethical considerations must precede launching new randomized controlled trials. Randomly assigning patients to different ICP-based management strategies may be an alternative. In addition, useful information may still be derived from observational studies with well-defined inclusion criteria, management plans, and standardized outcomes measures. It remains to be elucidated at which time point invasive monitoring and ICP-based management should be initiated to provide the greatest benefit. Most of the included studies had initiated treatment in comatose patients. However, it is possible that better outcomes could be achieved with earlier intervention. Finally, although EVD insertion was mainly sought for ICP monitoring or CSF diversion, novel evidence may extend its use toward CSF biomarker tracking [43].

Based on the findings of this review, we identified the need for more data to support evidence-based guidelines with a structured approach to the use of invasive ICP management strategies in community-acquired ABM [44]. Relying on the study findings, clinical experience, and the guidelines issued by the Swedish Society for Infectious Diseases [18], a strategy is suggested in which all patients with neurological deterioration and elevated lumbar pressure should be treated with invasive ICP monitoring (Fig. 3).

Fig. 3
figure 3

Suggested management of patients with suspicion of ABM based on available guidelines, with the addition of indications for invasive ICP monitoring and ICP-targeted therapy (based on low certainty evidence). ABM, acute bacterial meningitis, CT, computed tomography, EVD, external ventricular drain, GCS, Glasgow Coma Scale, ICP, intracranial pressure, ICU, intensive care unit, LP, lumbar puncture

Conclusions

This review provides insight into the role of invasive ICP monitoring and ICP-based management in the treatment of ABM. The data highlight the association between elevated ICP and mortality, and considerably higher ICP values are found in nonsurvivors compared with survivors. The available evidence is of limited quality but points toward enhanced patient outcomes in community-acquired ABM, with the use of a treatment strategy aiming to normalize ICP using continuous invasive monitoring and CSF diversion techniques (Fig. 3). This is relevant in the most severely affected patients with evidence of elevated ICP who deteriorate despite standard treatment with antibiotics and corticosteroids. Continued research efforts through high quality studies are crucial to determine when and how to employ these strategies to improve outcomes in ABM.